# A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

> **NCT06363084** · — · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 64 (actual)

## Conditions studied

- Resectable Pancreatic Cancer

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT06363084
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-01
- **Primary completion:** 2022-07-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363084, "A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06363084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*